Can new HIV drug mixes keep more children Virus-Free?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: 1. Aged ≥ 4 weeks to \<15 years\* with confirmed HIV infection 2. Weight ≥3kg and \<30kg\* 3. Written informed consent obtained (and assent if applicable) 4. Willing to adhere to a minimum of 48 weeks' follow-up * Upper limits of 15 years and 30kg are for initial treatment options and may be amended when further treatment options are introduced (through a protocol amendment) ART-NAÏVE 1. Planning to start first-line ART 2. Virologically unsuppressed with VL ≥400 c/mL at screening ART-EXPERIENCED 1. ART-experienced, and on DTG-based ART, and have been on DTG-based ART for at least 6-months prior to screening 2. Virologically unsuppressed for at least 3 months, demonstrated by two consecutive VLs ≥400 c/mL in the last year; the second VL must be at screening 3. Received adherence counselling as per standard practice prior to screening EXCLUSION CRITERIA 1. Alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN), OR both ALT ≥3xULN and bilirubin ≥2xULN at screening\*\* 2. Severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) 3. Severe renal impairment, defined as creatinine clearance \<30 mL/min/1.73m2, at screening\*\* 4. Severe life-threatening illness (not expected to survive beyond two weeks) as determined by the investigator's clinical judgment. 5. Eligible for less than two permitted treatment options based on tables 3 (ART-naive participants) and 4 (ART-experienced participants) 6. Concurrent participation in another clinical trial of an investigational medicinal product (IMP), medical device or other intervention. * If ALT, bilirubin or creatinine results are available before randomisation and meet exclusion criteria, the child should not be randomised. However, randomisation may proceed while awaiting these results. If results become available after randomisation and meet exclusion criteria, the participant must be recalled and withdrawn from the trial and the InCTU trial physician contacted to discuss clinical management.